Effect of Linagliptin on Diabetic patients with COVID-19

Phase 3

Recruiting

Conditions: COVID-19.
COVID-19, virus identified
U07.1

Registration Number: IRCT20210812052156N1

Lead Sponsor: Gonabad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 70

Inclusion Criteria

Consent to participate in research
Diabetes
Patients admitted to the ward with definite diagnosis of COVID-19 with PCR
Disease severity of mild to moderate

Exclusion Criteria

Lack of interest to cooperate in research
History of allergies to Linagliptin
Taking interactive drugs at simultaneous use with linagliptin, according to FDA definition
Adverse drug reactions occurrence

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Peripheral capillary oxygen saturation. Timepoint: From the beginning of admission to the hospital and daily during admission. Method of measurement: Pulse oximeter.;Requirement of non-mechanical ventilation. Timepoint: From the beginning of admission to the hospital and discharge time. Method of measurement: Patient's file in hospital.;Requirement of mechanical ventilation. Timepoint: From the beginning of admission to the hospital and discharge time. Method of measurement: Patient's file in hospital.;Hospitalization duration. Timepoint: From the beginning of admission to the hospital and discharge time. Method of measurement: Patient's file in hospital.;Requirement of ICU. Timepoint: From the beginning of admission to the hospital and discharge time. Method of measurement: Patient's file in hospital.;Mortality. Timepoint: At the end of study. Method of measurement: Patient's file in hospital.

Secondary Outcome Measures